9. The Future of Molecular and Biomolecular Imaging in Prostate Cancer

  1. Hashim U Ahmed MRCS, BM, BCh, BA(Hons)4,
  2. Manit Arya FRCS, FRCS(Urol)5,
  3. Peter Carroll MD, MPH6 and
  4. Mark Emberton FRCS (Urol), FRCS, MD, MBBS, BSc4,7
  1. Michael S. Gee MD, PhD1,2,3 and
  2. Mukesh G. Harisinghani MD3

Published Online: 10 NOV 2011

DOI: 10.1002/9781444346893.ch9

Focal Therapy in Prostate Cancer

Focal Therapy in Prostate Cancer

How to Cite

Gee, M. S. and Harisinghani, M. G. (2011) The Future of Molecular and Biomolecular Imaging in Prostate Cancer, in Focal Therapy in Prostate Cancer (eds H. U. Ahmed, M. Arya, P. Carroll and M. Emberton), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444346893.ch9

Editor Information

  1. 4

    Division of Surgery and Interventional Sciences, University College London, London, UK

  2. 5

    Department of Urology, University College London, London, UK

  3. 6

    Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

  4. 7

    NIHR UCL/UCH Comprehensive Biomedical Research Centre, London, UK

Author Information

  1. 1

    Abdominal Imaging and Interventional Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

  2. 2

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

  3. 3

    Department of Radiology, Harvard University, Boston, MA, USA

Publication History

  1. Published Online: 10 NOV 2011
  2. Published Print: 2 OCT 2011

ISBN Information

Print ISBN: 9781405196499

Online ISBN: 9781444346893

SEARCH

Keywords:

  • molecular imaging;
  • biomolecular imaging;
  • MRI;
  • MR spectroscopy;
  • diffusion-weighted imaging;
  • PET;
  • ultrasmall superparamagnetic iron oxide

Summary

Conventional imaging technologies evaluate structural anatomy related to intrinsic contrast differences among tissues. In contrast, molecular imaging evaluates changes in cellular physiology and function accompanying disease that are likely to be earlier and more sensitive disease manifestations than anatomically visible lesions. Additionally, molecular imaging seeks to noninvasively evaluate specific molecular pathways in vivo that contribute to the malignant phenotype and as newer cancer therapies become increasingly molecule-specific, molecular imaging can potentially provide noninvasive determination of patients likely to benefit from treatment as well as early therapy response. This article reviews current and emerging molecular imaging technologies relevant to prostate cancer.